mHealth to aid clinical trial decentralisation and expedite the drug development process

eTradeWire News/10538679
Patient participation is a fundamental requirement to the overall success of clinical trials. So, lateral flow based mHealth technology needs to be utilised to overcome clinical trial patient recruitment and retention issues.

YORK, England - eTradeWire -- The concept of patient centricity is ensuring the patient is kept informed throughout the process, they understand the outputs of the trial, and minimise the burden on the patient. This enables pharmaceutical companies to meet patient expectations, improve trial success rates, and speed up the development timelines of new drugs.

One key outcome of this change is the move towards clinical trial decentralisation, where trials are built around patients in their homes, or in their community, through remote visits and monitoring. This offers significant advantages of convenience for the patient which in turn increases patient recruitment.

More on eTradeWire News
One approach employed is 'smart sampling' where patients receive a sample collection pack at their home where they follow the clear instructions provided, collect and package the required sample and send it to the laboratory for analysis.

Other clinical trials however are going one step further and are bringing testing to the patient's home, or community healthcare centres, through rapid near patient testing. This approach is providing real time results, enabling quick patient enrolment, ensuring retention of participants, and empowering patients.

Breaking down the barriers of traditional clinical trials

Lateral flow immunoassay technology is well placed to provide the solution for patient-centric testing in clinical trials. Learn more by visiting https://www.abingdonhealth.com/articles/mhealth-aid-clinical-trial-decentralisation/

Source: Abingdon Health
stats
Filed Under: Medical

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on eTradeWire News